OR WAIT null SECS
© 2023 MJH Life Sciences and Consultant Live. All rights reserved.
The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.
March 17, 2023
A phase 2a trial of provides data detailing the effects of inaxaplin, a small molecule APOL1 inhibitor, on urinary protein-to-creatinine ratio in people with focal segmental glomerulosclerosis and two APOL1 variants.
March 04, 2023
At ACC.23, our editorial team sat down with a pair of leaders in cardiometabolic health to get their perspective on the growing intersectionality of cardiovascular and chronic kidney disease and how patients have been the beneficiaries of this growing recognition.
March 03, 2023
Results from the NOSTONE trial suggest the incidence of recurrence did not differ among patients receiving hydrochlorothiazide once daily at a dose of 12.5 mg, 25 mg, or 50 mg or once-daily placebo.
February 21, 2023
The company announced more feedback from the FDA after receiving a Complete Response Letter last March.
February 01, 2023
Announced on February 1, the US Food and Drug Administration's approval of daprodustat (Jesduvroq) represents their first approval of an oral agent for the treatment of anemia caused by chronic kidney disease in people on dialysis.
January 31, 2023
The FDA has set a PDUFA date for daprodustat for February 1 for adult patients with chronic kidney disease.
January 16, 2023
The 2022 updated guidelines includes 13 recommendations and 52 practice points for clinicians caring for patients with diabetes and chronic kidney disease.
January 11, 2023
There was no significant differences in creatinine or estimated glomerular filtration rate between the readmission group and the no readmission group.
January 10, 2023
Results from the REGARDS study suggest traditional CKD risk factors were associated with higher risk of incident CKD and eGFR decline in Black individuals, compared to White individuals.
January 04, 2023
The topline phase 2b data shows both 75 mg and 150 mg doses of atacicept resulted in a 31% mean reduction in proteinuria.